# Quercetin 500 mg daily × Reduced MRI liver fat over 12 weeks — Evidence Check

Verdict 2955 · Evidence Check

Stored-material review date: Not recorded  
Original evidence cut-off: 2026-08-26  
Review-criteria version: 1.0  
Public page/material preparation date: 2026-10-12

Clinical papers were not read directly; existing review summaries were checked. No new clinical-literature search was performed. Unverified does not mean that research is absent or that there is no effect.

## Assessment scope

- Population: Single crossover trial in nonalcoholic fatty liver disease: 41 randomized and 36 completed. Detailed eligibility/baseline, sequence/period populations, MRI observations/denominators and exclusions/missingness are unverified. Do not sum two periods/measures from the same participants as independent trials/participants.
- Ingredient, formulation and route: Quercetin 500 mg daily as the original study condition. Product/batch, raw material/formulation, actual adherence/stopping and concomitant exposure are unverified. Do not convert this to effects of other polyphenols/foods, products or doses, or create new intake/treatment instructions.
- Dose: Preserve the original design of 12 weeks of quercetin or placebo followed by crossover after a 4-week washout. Actual sequence/period-specific exposure/completion, carryover/return to baseline and visit windows are unverified. Do not sum/convert new total duration/exposure.
- Comparator: Randomized double-blind placebo-controlled crossover comparison. Placebo/sensory matching, sequence allocation/concealment, MRI-assessor/analyst masking, concomitant diet/activity and original crossover models/missingness/adherence are unverified. Do not inherit original design/ITT accounts as current procedural verification.
- Measured outcome: Selected statistically positive 12-week MRI-PDFF intrahepatic-lipid surrogate. Preserve quercetin-period 11.5%±6.4 to 9.6%±5.8, the original approximate −1.9 percentage points, placebo-period change −0.1%±2.6, P=.013 and multiplicity-adjusted P=.028. Original %/%p wording is retained separately in the preserved original; do not create new changes/between-treatment differences, ratios/CIs or unit corrections. The type of ± quantity, within-person/period models, observed/ITT denominators and exact estimates are unverified. Distinguish the historical checking scope for between-treatment CIs and prespecified minimum MRI thresholds.
- Duration: The MRI primary outcome is at 12 weeks; distinguish the 4-week washout/crossover from actual measurement in each period. Post-treatment durability, overall long-term/clinical/harm outcomes are unverified. Do not calculate a new total follow-up duration from original periods.
- Questions outside this scope: New effect/change/response-rate/CI calculations or arbitrary %/%p corrections from MRI baseline/final values, placebo change, original approximate −1.9 percentage points/P values/± quantities and sample sizes; Summing two crossover periods/the same participants as new independent trials/participants, or deriving hypothetical total duration/exposure from 12 weeks/4 weeks; Filling an ITT account with unverified observed denominators, imputation models or an all-completer population; Turning weight correlation and MRI benefit into confirmation of direct hepatic causation/separated mediation, or calculating new direct effects; Reusing MRI/liver-enzyme/other secondary outcomes as improved cirrhosis/hospitalization/death, or exactly zero clinical effects/equivalence; Inheriting historical CI/funding checking in abstracts/public tables/full text as current whole external-document reading/review; Turning undisclosed manufacturer support, institutional affiliations/no-COI declarations and original I2 into absence of each support item/current independence verification; Turning original safety non-reporting/nonsignificance and rare-harm limitations into zero harms or treatment-safety certification; Creating currently absent clinical original reports/registration/follow-up materials or invented citations/values; Inheriting parent scores/axes and historical cross-checking as subclaim scores/current review/external reading; New calculations, hypothetical values, effects/CIs, grades, independence certification or product-intake/diet/activity/testing/treatment implementation guidance

## Checklist items

### N01 · Selected 12-week MRI outcome and original values

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the subclaim C and statistically positive surrogate note for reduced MRI liver fat over 12 weeks. Parent C with 54 points and original axes are parent-verdict context.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. The subclaim lacks score, status and axes; do not fill them with parent values. Do not create a new grade/effect or certification of clinical outcomes. Content review remains incomplete.
- Reason for missing information: The subclaim lacks score, status and axes; do not fill them with parent values. Do not create a new grade/effect or certification of clinical outcomes.
- Required materials and conditions: Selected existing question, grade/note, parent context and presence of score/status/axes
- Materials to obtain first: Data distinguishing the selected row from the original parent verdict
- Further research: Connect the original question to additional materials in proposed update research; no new investigation, calculation or trial is performed now.
- Conditions for verification: Selected existing question, grade/note, parent context and presence of score/status/axes requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Selected existing question, grade/note, parent context and presence of score/status/axes to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design
- Related sources: S01

### N02 · Participants with nonalcoholic fatty liver disease

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original population of 41 participants with nonalcoholic fatty liver disease. Do not generalize to all fatty liver/liver diseases or other populations.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Detailed eligibility, age/baseline liver fat, weight/metabolic/comorbid conditions and sequence-specific characteristics are unverified. Content review remains incomplete.
- Reason for missing information: Detailed eligibility, age/baseline liver fat, weight/metabolic/comorbid conditions and sequence-specific characteristics are unverified.
- Required materials and conditions: Disease, recruitment/eligibility, baseline risk and arm/period characteristics
- Materials to obtain first: Recruitment/eligibility, baseline and sequence/period-specific participant data
- Further research: Propose follow-up research on population conditions and applicability; no new investigation, calculation or trial is performed now.
- Conditions for verification: Disease, recruitment/eligibility, baseline risk and arm/period characteristics requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Disease, recruitment/eligibility, baseline risk and arm/period characteristics to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design
- Related sources: S01

### N03 · Quercetin 500 mg and formulation

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve quercetin 500 mg daily as the original study condition. Do not turn this into effects of every polyphenol/food or other products.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Raw material/manufacturing, product/batch, detailed composition, actual use/adherence and supply are unverified. Do not create intake instructions, conversions or product recommendations. Content review remains incomplete.
- Reason for missing information: Raw material/manufacturing, product/batch, detailed composition, actual use/adherence and supply are unverified. Do not create intake instructions, conversions or product recommendations.
- Required materials and conditions: Specific study product, formulation/ingredients/batch and exposure
- Materials to obtain first: Product/batch, composition, supply and actual exposure data
- Further research: Propose follow-up research distinguishing formulation from result attribution; no new investigation, calculation or trial is performed now.
- Conditions for verification: Specific study product, formulation/ingredients/batch and exposure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Specific study product, formulation/ingredients/batch and exposure to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed
- Related sources: S01

### N04 · Placebo and crossover comparison

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original randomized double-blind placebo-controlled crossover design. Do not use two periods from the same participants as independent trials/participants.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Placebo identity/matching, sequence/period-specific exposure/adherence, concomitant conditions and actual deviations are unverified. Content review remains incomplete.
- Reason for missing information: Placebo identity/matching, sequence/period-specific exposure/adherence, concomitant conditions and actual deviations are unverified.
- Required materials and conditions: Actual placebo, sensory matching and conditions in each period
- Materials to obtain first: Placebo/matching, period-specific exposure and adherence/deviation data
- Further research: Propose follow-up research on comparator conditions and period-specific comparison definitions; no new investigation, calculation or trial is performed now.
- Conditions for verification: Actual placebo, sensory matching and conditions in each period requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Actual placebo, sensory matching and conditions in each period to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application
- Related sources: S01

### N05 · 12 weeks and four-week washout

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original account of 12 weeks of quercetin or placebo followed by crossover after a 4-week washout. Do not sum or convert a new total duration/exposure.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Individual period starts/completion, washout adherence, subsequent return to baseline, actual assessment windows and stopping are unverified. Content review remains incomplete.
- Reason for missing information: Individual period starts/completion, washout adherence, subsequent return to baseline, actual assessment windows and stopping are unverified.
- Required materials and conditions: Intervention/measurement periods, washout and actual sequence
- Materials to obtain first: Sequence/period, washout and individual exposure/measurement data
- Further research: Propose follow-up research on time/carryover and observed results; no new investigation, calculation or trial is performed now.
- Conditions for verification: Intervention/measurement periods, washout and actual sequence requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Intervention/measurement periods, washout and actual sequence to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design
- Related sources: S01

### N06 · Randomized sequence and concealment

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the randomized crossover trial and 41 randomized participants as recorded.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Sequence-specific denominators, generation/concealment, blocking/stratification, access/changes and actual implementation documents are unread. A design label alone does not certify absence of bias. Content review remains incomplete.
- Reason for missing information: Sequence-specific denominators, generation/concealment, blocking/stratification, access/changes and actual implementation documents are unread. A design label alone does not certify absence of bias.
- Required materials and conditions: Crossover allocation sequence, generation/concealment and actual procedures
- Materials to obtain first: Original sequence-allocation, access/change and actual participant-flow data
- Further research: Propose follow-up research on allocation and period-specific population relationships; no new investigation, calculation or trial is performed now.
- Conditions for verification: Crossover allocation sequence, generation/concealment and actual procedures requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Crossover allocation sequence, generation/concealment and actual procedures to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M08 §8.1–8.2.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M08 §8.2.2, M15 §15.3.1; custom application
- Related sources: S01

### N07 · Masking and MRI assessment

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the double-blind design.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Actual masking of participants/researchers, MRI measurement/readers and analysts, maintenance/unmasking and imaging/region-of-interest standards are unverified. Content review remains incomplete.
- Reason for missing information: Actual masking of participants/researchers, MRI measurement/readers and analysts, maintenance/unmasking and imaging/region-of-interest standards are unverified.
- Required materials and conditions: Role-specific masking, measurement/image assessment and analysis procedures
- Materials to obtain first: Role-specific masking and MRI measurement/reading/analysis records
- Further research: Propose follow-up research on measurement/assessment bias and MRI results; no new investigation, calculation or trial is performed now.
- Conditions for verification: Role-specific masking, measurement/image assessment and analysis procedures requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Role-specific masking, measurement/image assessment and analysis procedures to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M08 Table 8.2.a, M03 §3.2.4; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design
- Related sources: S01

### N08 · MRI-PDFF and the 12-week measure

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: The original account describes MRI-PDFF intrahepatic lipid as an imaging surrogate and the 12-week primary outcome. It is distinct from cirrhosis, hospitalization and death.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Measurement/regions of interest, actual visits/repeats, baseline/final/period-specific comparison definitions and arm-specific observations are unverified. Content review remains incomplete.
- Reason for missing information: Measurement/regions of interest, actual visits/repeats, baseline/final/period-specific comparison definitions and arm-specific observations are unverified.
- Required materials and conditions: Definition, units/measurement and timing of the intrahepatic-lipid measure
- Materials to obtain first: Original MRI measure, measurements/repeats and period/observation data
- Further research: Propose follow-up research distinguishing imaging measures from other outcomes; no new investigation, calculation or trial is performed now.
- Conditions for verification: Definition, units/measurement and timing of the intrahepatic-lipid measure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Definition, units/measurement and timing of the intrahepatic-lipid measure to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M03 §3.2.4; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary
- Related sources: S01

### N09 · Quercetin-period baseline and final values

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve quercetin-period 11.5%±6.4 to 9.6%±5.8 exactly. The manuscript’s approximate −1.9 percentage points is an existing historical reported/explanatory value, not a calculation performed now.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Arm/sequence, period-baseline/final observations, the type of ± quantity, models/adjustment and individual values are unverified. Do not calculate new changes, response rates or CIs. Content review remains incomplete.
- Reason for missing information: Arm/sequence, period-baseline/final observations, the type of ± quantity, models/adjustment and individual values are unverified. Do not calculate new changes, response rates or CIs.
- Required materials and conditions: Periods/populations, dispersion and distinction from change in original MRI values
- Materials to obtain first: Period-specific baseline/final, dispersion/observation and original-estimate data
- Further research: Propose follow-up research on final values/change and period-specific analysis definitions; no new investigation, calculation or trial is performed now.
- Conditions for verification: Periods/populations, dispersion and distinction from change in original MRI values requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Periods/populations, dispersion and distinction from change in original MRI values to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design
- Related sources: S01

### N10 · Placebo change and units

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original placebo-period change of −0.1%±2.6. Keep the Korean concise summary’s %p wording in the whole original summary; do not arbitrarily correct units or create new final values/between-treatment differences.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Placebo-period baseline/final values, exact change definitions/units, the type of ± quantity, observed denominators/models and period matching are unverified. Content review remains incomplete.
- Reason for missing information: Placebo-period baseline/final values, exact change definitions/units, the type of ± quantity, observed denominators/models and period matching are unverified.
- Required materials and conditions: Placebo-period change/final values, original units and estimands
- Materials to obtain first: Original placebo-period values/units, change/observations and analysis data
- Further research: Propose follow-up research distinguishing original estimands/units and comparison relationships; no new investigation, calculation or trial is performed now.
- Conditions for verification: Placebo-period change/final values, original units and estimands requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Placebo-period change/final values, original units and estimands to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design
- Related sources: S01

### N11 · P=.013 and adjusted P=.028

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve between-treatment P=.013 and multiplicity-adjusted P=.028 exactly. Do not calculate/certify new risk ratios/response rates, exact effects/CIs or clinical success.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Period/sequence, within-person correlation, adjustment/multiplicity methods, test lists and original estimates/outputs are unread. Content review remains incomplete.
- Reason for missing information: Period/sequence, within-person correlation, adjustment/multiplicity methods, test lists and original estimates/outputs are unread.
- Required materials and conditions: Original test for the selected comparison, multiplicity/models and precision
- Materials to obtain first: Original analyses/SAP, models, multiplicity and exact-output data
- Further research: Propose follow-up research on tests/multiplicity and uncertainty; no new investigation, calculation or trial is performed now.
- Conditions for verification: Original test for the selected comparison, multiplicity/models and precision requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Original test for the selected comparison, multiplicity/models and precision to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design
- Related sources: S01

### N12 · Between-treatment CI and historical checking scope

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original statement that a between-treatment 95% CI was absent within the historically checked abstract/public-result-table scope. Only the preserved summary is read now; do not extend this to absence from the whole paper.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Original estimates/outputs, whole text/supplements and current CI/analysis data are unread. Do not create a new CI from original ± values, P values or sample sizes. Content review remains incomplete.
- Reason for missing information: Original estimates/outputs, whole text/supplements and current CI/analysis data are unread. Do not create a new CI from original ± values, P values or sample sizes.
- Required materials and conditions: Precision and abstract/public-table checking versus current reading scope
- Materials to obtain first: Original paper/supplements, exact outputs and between-treatment CI data
- Further research: Propose update research distinguishing precision data from materials actually read; no new investigation, calculation or trial is performed now.
- Conditions for verification: Precision and abstract/public-table checking versus current reading scope requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Precision and abstract/public-table checking versus current reading scope to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design
- Related sources: S01

### N13 · Prespecified important MRI threshold

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original statement that no minimum clinically important MRI-PDFF reduction threshold was declared. Do not promote statistical positivity to long-term clinical outcomes or confirmatory success.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Prespecified criteria, power/plans, correspondence to clinical measures and exact estimates/CIs are unverified. Content review remains incomplete.
- Reason for missing information: Prespecified criteria, power/plans, correspondence to clinical measures and exact estimates/CIs are unverified.
- Required materials and conditions: Prespecified minimum clinically important difference and interpretation/success definitions
- Materials to obtain first: Prespecified plans, important differences/power and clinical-correspondence data
- Further research: Propose research distinguishing statistical results from important differences/clinical meaning; no new investigation, calculation or trial is performed now.
- Conditions for verification: Prespecified minimum clinically important difference and interpretation/success definitions requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Prespecified minimum clinically important difference and interpretation/success definitions to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M15 §15.3.1–15.3.3; custom application; M08 Table 8.2.a, M04 §4.6.3; custom application; M03 §3.2.4; custom extension boundary
- Related sources: S01

### N14 · 41 to 36: completion and analysis

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve 41 randomized and 36 completed exactly. Do not calculate/declare new missing counts/rates, summed periods or a completer-only ITT population.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Sequence/period-specific completion, endpoint observations, withdrawal/missingness reasons, actual analysis populations and sensitivity analyses are unverified. Content review remains incomplete.
- Reason for missing information: Sequence/period-specific completion, endpoint observations, withdrawal/missingness reasons, actual analysis populations and sensitivity analyses are unverified.
- Required materials and conditions: Randomized/completed participants, period-specific observations/analysis and missingness
- Materials to obtain first: Sequence/period-specific flow, observation/missingness and analysis data
- Further research: Propose follow-up research on selected populations and missing-data assumptions; no new investigation, calculation or trial is performed now.
- Conditions for verification: Randomized/completed participants, period-specific observations/analysis and missingness requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Randomized/completed participants, period-specific observations/analysis and missingness to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M08 §8.2.2, M15 §15.3.1; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application
- Related sources: S01

### N15 · ITT and crossover model

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original account that ITT results were reported. Do not fill this in as verified MRI observations/denominators in every period for all 41 participants or a particular imputation model.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. MRI ITT denominators, within-person correlation, period/sequence, missing-data models, sensitivity analyses and actual original analyses are unread. Content review remains incomplete.
- Reason for missing information: MRI ITT denominators, within-person correlation, period/sequence, missing-data models, sensitivity analyses and actual original analyses are unread.
- Required materials and conditions: Actual ITT/allocation and period/sequence/within-person comparison definitions
- Materials to obtain first: ITT/crossover models and period-specific denominator/missingness/sensitivity data
- Further research: Propose follow-up research on allocation/period, missing-data assumptions and estimation; no new investigation, calculation or trial is performed now.
- Conditions for verification: Actual ITT/allocation and period/sequence/within-person comparison definitions requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Actual ITT/allocation and period/sequence/within-person comparison definitions to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M08 §8.2.2, M15 §15.3.1; custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design; M15 §15.3.1–15.3.3; custom application
- Related sources: S01

### N16 · Washout, carryover and period effects

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original design of crossover after a 4-week washout. Do not treat the two periods as different participants or independent replication.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Return to baseline, carryover/sequence/period effects, tests/interactions, actual analyses and exposure adherence are unverified. Content review remains incomplete.
- Reason for missing information: Return to baseline, carryover/sequence/period effects, tests/interactions, actual analyses and exposure adherence are unverified.
- Required materials and conditions: Carryover/sequence, period-specific baselines and analytical handling
- Materials to obtain first: Period baselines, carryover/sequence handling and model/exposure data
- Further research: Propose research distinguishing carryover/period effects from same-participant outcomes; no new investigation, calculation or trial is performed now.
- Conditions for verification: Carryover/sequence, period-specific baselines and analytical handling requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Carryover/sequence, period-specific baselines and analytical handling to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is custom design
- Related sources: S01

### N17 · Weight change and correlation

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original weight change of −1.5±2.6 kg during quercetin versus −0.2±1.8 kg during placebo and its correlation with liver-fat reduction. Direct hepatic and weight-mediated effects were not separated.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Correlation estimates, timing/populations, models/mediation analyses, concomitant activity/diet and original individual data are unverified. Do not calculate a new direct hepatic effect. Content review remains incomplete.
- Reason for missing information: Correlation estimates, timing/populations, models/mediation analyses, concomitant activity/diet and original individual data are unverified. Do not calculate a new direct hepatic effect.
- Required materials and conditions: Separate weight/liver-fat measures and causal/mediation relationships
- Materials to obtain first: Individual weight/fat trajectories, correlation/mediation models and concomitant exposure data
- Further research: Propose follow-up research distinguishing weight/exposure from result attribution; no new investigation, calculation or trial is performed now.
- Conditions for verification: Separate weight/liver-fat measures and causal/mediation relationships requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Separate weight/liver-fat measures and causal/mediation relationships to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M08 §8.2.2, M15 §15.3.1; custom application; M03 §3.2.4; custom extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design
- Related sources: S01

### N18 · Null liver-enzyme and other secondary outcomes

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original account that liver enzymes and other secondary endpoints were not significant. Do not reuse MRI positivity as benefits for liver enzymes or every clinical outcome.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Each measure/time point, denominator, value/estimate/CI, multiplicity and hierarchy are unverified. Do not turn nonsignificance into an exactly zero effect or equivalence. Content review remains incomplete.
- Reason for missing information: Each measure/time point, denominator, value/estimate/CI, multiplicity and hierarchy are unverified. Do not turn nonsignificance into an exactly zero effect or equivalence.
- Required materials and conditions: Definitions/hierarchy of other endpoints, original results and the selected measure
- Materials to obtain first: Original plans/measurements, values/estimates and CIs for each secondary measure
- Further research: Propose research on other measures, discordance and uncertainty; no new investigation, calculation or trial is performed now.
- Conditions for verification: Definitions/hierarchy of other endpoints, original results and the selected measure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Definitions/hierarchy of other endpoints, original results and the selected measure to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is custom design; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is custom design; M08 Table 8.2.a, M04 §4.6.3; custom application; M15 §15.3.1–15.3.3; custom application
- Related sources: S01

### N19 · Concomitant exposure, adherence and subsequent care

Verification status: Unverified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original scope of the specific quercetin/placebo crossover.
- Why unverified: Information currently needed is unverified in the preserved summary. Diet/activity, weight management, drugs/supplements, actual intake/stopping/crossover and exposure in each period are unverified. Do not create new weight/diet/exercise, treatment or intake instructions. Content review remains incomplete.
- Reason for missing information: Diet/activity, weight management, drugs/supplements, actual intake/stopping/crossover and exposure in each period are unverified. Do not create new weight/diet/exercise, treatment or intake instructions.
- Required materials and conditions: Arm/period-specific activity/diet, drugs/products and actual exposure
- Materials to obtain first: Period-specific concomitant exposure, adherence/changes and weight/management records
- Further research: Propose research on concomitant exposure and result attribution; no new investigation, calculation or trial is performed now.
- Conditions for verification: Arm/period-specific activity/diet, drugs/products and actual exposure requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Arm/period-specific activity/diet, drugs/products and actual exposure to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; custom application; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design
- Related sources: S01

### N20 · ChiCTR and prespecified plans

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original registration-field value ChiCTR2100047904. A registration number alone does not verify prespecification, original plans or CIs/criteria now.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Registration history, protocol/SAP, recruitment/measurement/analysis timing, multiplicity and amendments are unread. Content review remains incomplete.
- Reason for missing information: Registration history, protocol/SAP, recruitment/measurement/analysis timing, multiplicity and amendments are unread.
- Required materials and conditions: Registration identity, plans/changes and correspondence to reports
- Materials to obtain first: Registration history, protocol/SAP and report/amendment data
- Further research: Propose research connecting prespecified plans to result reporting; no new investigation, calculation or trial is performed now.
- Conditions for verification: Registration identity, plans/changes and correspondence to reports requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Registration identity, plans/changes and correspondence to reports to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M08 Table 8.2.a, M04 §4.6.3; custom application; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design
- Related sources: S01

### N21 · Funding-agency names and unverified scope

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original funding/Korean-English account that a separate joint funding-agency name was not identified in the public text. Do not turn this into no funding or independence certification.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Actual providers/contracts, research/analysis/writing/publication roles and complete disclosures are unread now. Content review remains incomplete.
- Reason for missing information: Actual providers/contracts, research/analysis/writing/publication roles and complete disclosures are unread now.
- Required materials and conditions: Funders, roles and the scope of the public text
- Materials to obtain first: Funding contracts, providers/roles and original disclosures for each support item
- Further research: Propose update research on historical checking scope and current materials; no new investigation, calculation or trial is performed now.
- Conditions for verification: Funders, roles and the scope of the public text requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Funders, roles and the scope of the public text to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design
- Related sources: S01

### N22 · Manufacturer, product and analysis disclosures

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: The original account states that commercial-manufacturer funding, free products and outsourced analysis were not disclosed in the public text. Do not convert non-disclosure into no support or verification of all independence.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Manufacturing/supply, individual support, writing/publication fees and actual complete original disclosures are unread. Content review remains incomplete.
- Reason for missing information: Manufacturing/supply, individual support, writing/publication fees and actual complete original disclosures are unread.
- Required materials and conditions: Individual records of commercial funding/products and analysis/writing/publication support
- Materials to obtain first: Product/support, manufacturing/contribution and original writing/publication disclosures
- Further research: Propose research distinguishing gaps in individual disclosures/support; no new investigation, calculation or trial is performed now.
- Conditions for verification: Individual records of commercial funding/products and analysis/writing/publication support requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Individual records of commercial funding/products and analysis/writing/publication support to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: Chamgap independence/attribution conditions. The referenced official method sections do not certify every detail of these items; Data collection/selection principles in M04 §4.5–4.6; Access/reading separation and hyperlink rules are Chamgap design
- Related sources: S01

### N23 · Institutional affiliations and COI declarations

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original account of Army Medical University/Xinqiao Hospital affiliations and a no-competing-interests declaration. Institutional affiliation does not certify funding or current independence.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Staff/contributions, timing of relationships/employment, equity/other COIs and detailed disclosures are unread. Content review remains incomplete.
- Reason for missing information: Staff/contributions, timing of relationships/employment, equity/other COIs and detailed disclosures are unread.
- Required materials and conditions: Distinguish author affiliations/employment from contributions/interests
- Materials to obtain first: Author-specific affiliation/employment, contribution and original COI disclosures
- Further research: Propose research on declarations and author/institutional roles; no new investigation, calculation or trial is performed now.
- Conditions for verification: Distinguish author affiliations/employment from contributions/interests requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Distinguish author affiliations/employment from contributions/interests to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: Chamgap’s own independence/attribution conditions; official methodology sections in this pilot do not certify all these detailed items; M04 §4.5–4.6 material-collection/selection principles; separation of access/reading and hyperlink conventions are custom design; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design
- Related sources: S01

### N24 · Safety measures and rare harms

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Preserve the original account that significant between-treatment differences in routine blood and other safety measures and intervention-related adverse events were not reported, together with the limitation that 41 participants are too few to evaluate rare harms.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Arm/period-specific harm denominators/events, collection/stopping/relatedness/missingness and long-term/vulnerable populations are unverified. Do not turn non-reporting/nonsignificance into zero harms or safety certification. Content review remains incomplete.
- Reason for missing information: Arm/period-specific harm denominators/events, collection/stopping/relatedness/missingness and long-term/vulnerable populations are unverified. Do not turn non-reporting/nonsignificance into zero harms or safety certification.
- Required materials and conditions: Harm collection/definitions, populations/periods and original reporting scope
- Materials to obtain first: Harm collection, arm-specific denominators/events and stopping/follow-up data
- Further research: Propose research on harm-reporting scope and rare/long-term outcomes; no new investigation, calculation or trial is performed now.
- Conditions for verification: Harm collection/definitions, populations/periods and original reporting scope requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Harm collection/definitions, populations/periods and original reporting scope to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Supplement gaps in safety materials for the selected subclaim. Do not judge safety from MRI/clinical results or parent safety wording, or create harm-incidence estimates/new use instructions.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M19 §19.1.2–19.2.4; detailed distinctions are custom design; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4, M04 §4.6.3; custom application; M19 §19.1.2–19.2.4; custom application; M19 §19.1.2–19.2.4; custom application
- Related sources: S01

### N25 · Relationships within the same trial across periods/reports

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: Do not sum the single Li 2024/ChiCTR trial, 41 participants/36 completers, two periods/measurement times or MRI/weight/liver enzymes/sibling sheets as new independent trials/participants. Original R1/I2 are historical axes.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. External correspondence of same-participant periods/endpoints, unique populations/follow-up reports and independent replication under matching conditions has not been checked. Do not invent follow-up reports. Content review remains incomplete.
- Reason for missing information: External correspondence of same-participant periods/endpoints, unique populations/follow-up reports and independent replication under matching conditions has not been checked. Do not invent follow-up reports.
- Required materials and conditions: Distinguish reports/trials/participants, crossover/measures and independent replication
- Materials to obtain first: Trial/registration/participant, period/endpoint/report relationships and separate evidence
- Further research: Propose research on same-data/period relationships and separate replication; no new investigation, calculation or trial is performed now.
- Conditions for verification: Distinguish reports/trials/participants, crossover/measures and independent replication requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Distinguish reports/trials/participants, crossover/measures and independent replication to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is a custom application; M04 §4.6.1–4.6.2, M15 §15.3.1; custom application; M04 §4.5, §4.6.3; limits on current material conversion reflect the review scope and custom design
- Related sources: S01

### N26 · Clinical outcomes and other formulations/durations

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: MRI positivity is not evidence of improved cirrhosis, hospitalization or death. Do not extend the specific 500 mg/12-week result to every polyphenol or other formulations/populations/long-term effects.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Direct clinical outcomes, post-treatment durability, other doses/populations/periods and harms are unverified. Do not create treatment/intake methods. Content review remains incomplete.
- Reason for missing information: Direct clinical outcomes, post-treatment durability, other doses/populations/periods and harms are unverified. Do not create treatment/intake methods.
- Required materials and conditions: Distinguish selected MRI results from actual clinical outcomes/outside populations
- Materials to obtain first: Additional clinical-endpoint, formulation/population and long-term follow-up materials
- Further research: Propose research distinguishing imaging from clinical outcomes and selected conditions; no new investigation, calculation or trial is performed now.
- Conditions for verification: Distinguish selected MRI results from actual clinical outcomes/outside populations requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Distinguish selected MRI results from actual clinical outcomes/outside populations to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M03 §3.2.4; custom extension boundary; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are custom design; M03 §3.2.1; detailed population conditions are custom design; M03 §3.2.2–3.2.3; reverse-direction labeling and test adaptation are custom design
- Related sources: S01

### N27 · Original axes, Korean/English text, dates and corrections

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: The whole preserved summary retains subclaim C/note, parent C with 54 points/Good, B/S/R1/I2/E+/B1, unrecorded precision, three false flags, empty override reasons, Korean/English text, 2026-08-26 and empty corrections/deliberation.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Historical cross-check/abstract/public-table/full-text checking accounts are not current external reading/review or newly fulfilled conditions. Do not fill absent subclaim score/status/axes or absent parent classification keys. Content review remains incomplete.
- Reason for missing information: Historical cross-check/abstract/public-table/full-text checking accounts are not current external reading/review or newly fulfilled conditions. Do not fill absent subclaim score/status/axes or absent parent classification keys.
- Required materials and conditions: Distinguish subclaim/parent values, original evidence date/corrections and history
- Materials to obtain first: Original verdict/corrections, amended manuscripts and human comments
- Further research: Propose update research on source-material changes and production versions; no new investigation, calculation or trial is performed now.
- Conditions for verification: Distinguish subclaim/parent values, original evidence date/corrections and history requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Distinguish subclaim/parent values, original evidence date/corrections and history to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed
- Related sources: S01

### N28 · Summary reading and externally unread materials

Verification status: Partly verified  
Reading scope: Summary read; external material unread

- Current findings: The preserved summary was read for production, and the Li 2024/PMID 39032786 citation/URL is linked. Paper/registration/protocol/SAP/disclosures remain unread, with no access attempted.
- Why unverified: Only corresponding information in the preserved summary is recorded; detailed original materials are unread and content review remains incomplete. Original URLs/registration and historical accounts do not raise current acquisition/reading/review status; external links/clicks have not been checked. Content review remains incomplete.
- Reason for missing information: Original URLs/registration and historical accounts do not raise current acquisition/reading/review status; external links/clicks have not been checked.
- Required materials and conditions: Actual reading for each material, citations/URLs and gaps in additional materials
- Materials to obtain first: Original reports/registration/plans/disclosures and human comments
- Further research: Propose scoped update research based on materials actually acquired; no new investigation, calculation or trial is performed now.
- Conditions for verification: Actual reading for each material, citations/URLs and gaps in additional materials requires corresponding original material/analysis scope and a distinction of unverified matters. Original wording is linked here; content review remains incomplete.
- Why this condition is needed: Distinguish Actual reading for each material, citations/URLs and gaps in additional materials to connect materials needed for the selected question with the current materials in this production item.
- Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
- Remaining uncertainty: This record links preserved-summary statements; it does not establish external-paper comparison, a new efficacy verdict or completed content review.
- Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design
- Related sources: S01

## Evidence and sources

### S01

Li N et al. 2024

[PubMed](https://pubmed.ncbi.nlm.nih.gov/39032786/)

Materials actually read: Summary read; external material unread  
Findings recorded in the summary: 11.5%±6.4 to 9.6%±5.8 versus placebo change −0.1%±2.6; P=0.013, adjusted P=0.028. Original grade C with 54 points: in the 41-participant double-blind crossover trial, quercetin-period liver fat changed from 11.5%±6.4 to 9.6%±5.8, an approximate 1.9-percentage-point reduction, versus placebo change −0.1%±2.6; between-treatment P=0.013 and multiplicity-adjusted P=0.028. The original approximate −1.9 percentage points already appears in the preserved manuscript as a historical reported/explanatory value, not a new calculation. Distinguish original absence of a CI/minimum important threshold, period/unit/weight-mediation gaps and currently unread external materials.  
Record level: Outcome wording in the stored summary  
Independent replication: S01 Li 2024/ChiCTR2100047904 is a single double-blind placebo-controlled crossover trial in nonalcoholic fatty liver disease, with 41 randomized and 36 completed. Distinguish original quercetin 500 mg/day, 12-week intervention and crossover after a 4-week washout from unverified actual sequence/period/exposure and ITT/observation/missing-data models. Quercetin-period MRI 11.5%±6.4 to 9.6%±5.8, original approximate −1.9 percentage points, placebo change −0.1%±2.6, P=.013 and adjusted P=.028 are original surrogate results, not new calculations. Do not arbitrarily correct %/%p wording; retain gaps in the type of ± quantity, between-treatment CI/important difference and original period/within-person estimates. Weight changes −1.5±2.6 kg versus −0.2±1.8 kg, correlation with MRI reduction/unseparated direct hepatic effects, nonsignificant liver enzymes/other secondary outcomes and untested clinical cirrhosis/hospitalization/death are distinct outcomes. Do not sum the same participants/arms, crossover periods, MRI/weight/liver enzymes, citations or sibling sheets as new independent trials/participants. Do not create follow-up reports/clinical effects or inherit original R1/I2 and historical abstract/public-table/full-text checking accounts as current review/external reading. Report/material-slot counts are not unique clinical trial/participant/independent-replication totals; no new sums or independence certification are performed.

| Material | Public availability | Access status | Actually read | Notes |
|---|---|---|---|---|
| Stored summary | Stored file | Stored summary | Summary read | Only stored-summary and bibliographic content was used for production. External material verification/review is not complete. |
| External paper | Public availability unverified; only bibliography links preserved | Unread; access not attempted | Not read | No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status. |
| Registration material | Public availability unverified; only bibliography links preserved | Unread; access not attempted | Not read | No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status. |
| Protocol | Public availability unverified; only bibliography links preserved | Unread; access not attempted | Not read | No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status. |
| Statistical analysis plan | Public availability unverified; only bibliography links preserved | Unread; access not attempted | Not read | No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status. |
| Funding, product-support and COI material | Public availability unverified; only bibliography links preserved | Unread; access not attempted | Not read | No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status. |

## Review criteria and methods

These are Chamgap's own application conditions, informed by the relevant sections of official methodological guidance. They do not constitute official assessment-tool certification or a new efficacy score.

- M03 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03) · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13 · Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions. · Preserved method HTML copies; no current method-content re-review or official tool execution
- M04 [Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04) · §4.5, §4.6.1–4.6.3, MECIR C42 · Distinguish studies from reports and link them; do not omit a study solely because results are unreported. · Preserved method HTML copies; no current method-content re-review or official tool execution
- M08 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08) · §8.1–8.2.3, Table 8.2.a · Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting. · Preserved method HTML copies; no current method-content re-review or official tool execution
- M15 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15) · §15.2.4, §15.3.1–15.3.3 · Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision. · Preserved method HTML copies; no current method-content re-review or official tool execution
- M19 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19) · §19.1.2, §19.2.1–19.2.4 · Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates. · Preserved method HTML copies; no current method-content re-review or official tool execution

## What the statuses mean

- Met: Status for necessary evidence confirmed after existing content review. No completion is declared in the current presentation.
- Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
- Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
- Review incomplete: Existing content review remains incomplete.
- Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
- Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
- Not applicable: Not used as a substitute for an evidence gap.
- Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
- Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

## Change history

2026-10-12 · Public page/materials 1.0. Public reader pages and material were prepared from the existing 28 items. No new clinical searches, verification-state changes or scoring were performed.